Resolution Therapeutics Announces a £26.6m Series A Financing from Syncona Ltd
Resolution Therapeutics Limited (“Resolution”), a biopharmaceutical company developing macrophage cell therapy to treat chronic diseases characterised by life-threatening inflammatory organ damage, today announced completion of a £26.6m Series A financing from Syncona Ltd (“Syncona”). Syncona entered into a collaboration with the University of Edinburgh Centre for Regenerative Medicine in 2018 which has provided the foundation of Resolution’s technology platform. The Series A funding is expected to deliver early clinical data for the company’s first product.
